Skip to main content
. 2022 Jan 27;31(4):793–803. doi: 10.1158/1055-9965.EPI-21-0996

Table 1.

Study participant characteristics from the EPIC study and the NSHDS.

Study population (n = 1,380)
Variables Cases (n = 690) Controls (n = 690)
Time to diagnosis, y, median (IQR) 10.6 (7.4–13.5) NA
Age, y, median (IQR) 58.0 (50.2–60.2) 57.7 (50.1–60.2)
BMI, kg/m2, median (IQR) 27.1 (25.0–29.8) 26.5 (24.5–28.7)
BMI groups, n (%) Underweight (<18.5) 0 (0.0) 2 (0.3)
Normal weight (18.5–24.9) 171 (24.8) 209 (30.3)
Overweight (25.0–29.9) 357 (51.7) 374 (54.2)
Obese (>30.0) 160 (23.2) 103 (15.1)
Unknown 2 (0.3) 1 (0.1)
Smoking status, n (%) Never 172 (24.9) 203 (29.4)
Former 289 (41.9) 263 (38.1)
Current 214 (31.0) 208 (30.2)
Unknown 15 (2.2) 16 (2.3)
Alcohol consumption, g/day, median (IQR) 9.4 (2.3–28.6) 7.9 (1.9–23.1)
Alcohol consumption groupsa, n (%) Zero intake 63 (9.1) 56 (8.1)
Below median intake 281 (40.7) 288 (41.7)
Above median intake 344 (49.9) 344 (49.9)
Unknown 2 (0.3) 2 (0.3)
Physical activity groups, n (%) Inactive 170 (24.7) 128 (18.6)
Moderately inactive 203 (29.4) 221 (32.0)
Moderately active 155 (22.5) 163 (23.6)
Active 121 (17.5) 136 (19.7)
Unknown 41 (5.9) 42 (6.1)
Serological levels, median (IQR) Androstenedione, pg/mL 701.1 (526.7–944.1) 720.8 (548.2–922.7)
Dehydroepiandrosterone, ng/mL 2.28 (1.45–3.54) 2.34 (1.50–3.47)
Estrone, pg/mL 29.1 (22.6–37.9) 28.2 (22.4–35.8)
Estradiol, pg/mL 18.9 (15.1–23.9) 19.1 (14.9–24.1)
Progesterone, pg/mL 74.1 (53.4–107.5) 78.3 (56.1–112.1)
Testosterone, ng/mL 4.10 (3.29–5.27) 4.41 (3.47–5.50)
Free estradiol, pg/mL 0.49 (0.39–0.61) 0.48 (0.38–0.62)
Free testosterone, pg/mL 75.8 (63.3–90.7) 77.6 (65.1–92.6)
SHBG, nmol/L 35.7 (26.2–47.0) 37.6 (28.6–51.0)

Abbreviations: IQR, interquartile range; y, years.

aBased on the control groups median of 7.9 g/day alcohol consumption.